SCHEMBL3343503

SCHEMBL3343503

COC(=O)NCCOC(c1cccc(C)c1)c1cccc(C(=O)O)c1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.40
REN P00797 1/20 0.40
ANPEP P15144 1/20 0.39
ENPEP Q07075 1/20 0.39
HTR1A P08908 2/20 0.38
ADRA1D P25100 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
GPR139 Q6DWJ6 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
POLB P06746 1/20 0.38
AKR1C3 P42330 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CASR P41180 1/20 0.37
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3641253 0.99 ALDH1A1 (0.41) ALDH1A1CYP2D6CYP2C19MAPTREN
SCHEMBL3338753 0.92 HTR1A (0.46) ALDH1A1MAPTANPEPENPEPHTR1A
SCHEMBL8076505 0.91 HTR1A (0.46) ALDH1A1MAPTANPEPENPEPHTR1A
SCHEMBL3344191 0.90 CASR (0.42) CYP2D6CYP2C19MAPTRENGPR139
Lithium Ion SCHEMBL3343498 0.88 REN (0.39) ALDH1A1CYP2D6CYP2C19RENHTR1A
SCHEMBL1567460 0.86 HTT (0.45) ALDH1A1CYP2C19MAPTRENGPR139
SCHEMBL1567463 0.86 HTT (0.45) ALDH1A1CYP2C19MAPTRENGPR139
SCHEMBL10068970 0.84 HTT (0.41) CYP2C19MAPTRENRAB9ACASR
SCHEMBL3343494 0.82 CASR (0.49) ALDH1A1HTR1AADRA1DADRA1AADRA1B
SCHEMBL3643578 0.82 CASR (0.42) MAPTHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
EP-2170815-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2010-04-07 EP disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160424-A1 RENIN INHIBITORS ACE, REN, DNPEP ALDH1A1 2175/4885CYP2D6 2754/4885CYP2C19 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.